Top pharmaceutical companies in conjunction with wealthy nations are to help prevent the spread of the swine flu virus in under developed nations.

Top pharmaceutical company Vanguard Pharmaceuticals has recently been expanding its operations into the Latin and South American Markets, with effects that could be beneficial for the distribution of a swine flu vaccine.

Roche share price hasn’t exceeded the 20% return since the first swine flu symptoms were reported in Mexico in April 2009, a clear indication that Tamiflu is not the solution to the swine flu pandemic. Relenza, produced by GlaxoSmithKline, is also reporting the same ineffective results primarily over children under 12.

The competitive advantage from top pharmaceutical companies has also been mimicked by the top biotech companies as the industry emerges as a leading player in the swine flu research. The swine flu pandemic is now recognized as one of the most profitable opportunities ever encountered by healthcare sector.

Strategic alliances are present in businesses throughout the world. Beneficial to both parties involved, these alliances are becoming common in the healthcare industry as the global scale of the swine flu pandemic requires team work and joint efforts.

CSL was one of the first to produce a flu vaccine and with potential contracts with the Australian government to supply 90% of its vaccine orders as well as orders form the US government totalling $180 million (US dollars); it makes CSL a very attractive investment choice. Howeve, CSL management has struggled to convert their achievements into profit, so CSL share price has remained stagnant for over 18 months.

Healthcare is a multi billion dollar a year industry and with aging baby-boomer investors helping to fuel production, this industry will continue. Global health problems like Cancer, HIV, Diabetes, and the swine flu pandemic mean there is no shortage of research and development to be done. And for investors, the discovery of the first swine flu vaccine will mean big profits.

The most viable choices for investors are pharmaceutical companies with approved registration for H1N1 virus research that have vaccines with several phases into clinical trials. Top pharmaceutical companies and biotech companies with the largest distribution networks participating in the swine flu vaccine research and production include…

BioSante´s innovative vaccine adjuvant and delivery system, BioVant, can increase the effectiveness of flu vaccines, including for the new swine flu vaccine. However, these results are based on per-clinical trials and BioSante’s achievements in this area are still on a research and development level.

The recent deaths of healthy people in the US and UK suggests the virus is mutating. We can only hope that the new altered swine flu virus doesn’t transmit as easily.